Uncontrolled Wet AMD: Drug Switch Can Mute Disease Activity

Phase 3 data from the 2023 ARVO meeting showed treatment with the monoclonal antibody improved visual acuity in some patients.

Related Keywords

Australia , Paris , France General , France , Sydney , New South Wales , Australian , Ramin Tadayoni , Mark Gillies , Brolucizumab Beovu , Iveric Bio , Srinivasr Sadda , Doheny Eye Institute , Genentech , University Of Paris , Association For Research , Macula Research Group , Novartis , Allergan , University Of Sydney Save Sight Institute , Saint Louis University Hospitals , California Los Angeles David Geffen School , Drug Administration , Sydney Save Sight , Exudative Age Related Macular Degeneration , Xudative Armd , Vision Care And Maintenance , Epimacular Membrane , Macular Dystrophy , Macular Amyloidosis , Visual Acuity , Drug Development , Vegf Vascular Endothelial Growth Factor , Vascular Endothelial Growth Factor , Ascular Endothelial Growth Factor Vegf , Vegf Inhibitor , Vascular Endothelial Growth Factor Inhibitor , Biologic Therapy , Vasculitis , Intraocular In ,